COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($) |
1 Months Ended | 12 Months Ended | ||||
|---|---|---|---|---|---|---|
Jan. 11, 2022 |
Mar. 28, 2019 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Sep. 30, 2019 |
Dec. 10, 2015 |
|
| Renumeration amount | $ 6,000 | |||||
| Consideration amount | $ 657,640 | 393,776 | ||||
| First payment owed | $ 145,000 | 70,138 | ||||
| Attorney's fees | $ 235,886 | |||||
| Interest rate | 10.00% | |||||
| Recognized loss on contingency | $ (322,000) | |||||
| Stock options grant | 10,000 | |||||
| Term of options | 3 years | |||||
| Consulting services valued | $ 18,946 | |||||
| Compensation for services, description | As of May 14, 2021, the Company has entered into four consulting agreements. In compensation for services: (i) one consultant shall receive a renumeration amount of $10,000-$12,500 per month and has earned 1% of the Company’s majority owned subsidiary, BioCorRx Pharmaceuticals as of May 7, 2021 based on FDA clearance of Company’s IND application; consulting agreement terminated in April 2021 (ii) one consultant shall receive common stock equivalent to $1,375 on the last day of each month; (iii) two consultants shall receive common stock equivalent to $3,750 on the last day of each month; and (iv) one consultant shall receive a remuneration amount of $3,500 per month | |||||
| common stock, par value | $ 0.001 | $ 0.001 | ||||
| Galligan Subscription and Royalty Agreement [Member] | ||||||
| Common stock, Shares issued | 200,000 | |||||
| Subscription and Royalty Agreement | $ 3,000,000 | |||||
| Royality percentage minimum | 10.00% | |||||
| Royality percentage maximum | 15.00% | |||||
| Lucido Subscription and Royalty Agreement [Member] | ||||||
| Royality percentage minimum | 10.00% | |||||
| Royality percentage maximum | 15.00% | |||||
| Purchase price | $ 15.00 | |||||
| Common stock | 200,000 | |||||
| Revenue per share | $ 37.50 | |||||
| Gross revenue per share | $ 25.00 | |||||
| Percent of aggregate purchase price | 65.00% | |||||
| Development and expansion expenses amount | $ 3,000,000 | |||||
| Option [Member] | ||||||
| Stock options description | (i) Company shall grant 10,000 incentive Stock Options upon achievement of U.S. $500,000 collected gross revenues, (ii) Company shall grant 20,000 incentive Stock Options to the Agent under its Stock Option Plan upon achievement of U.S. $1,000,000 collected gross revenues, (iii) Company shall grant 30,000 incentive Stock Options to the Agent under its Stock Option Plan upon achievement of U.S. $1,500,000 collected gross revenues, (iv) Company shall grant 40,000 incentive Stock Options to the Agent under its Stock Option Plan upon achievement of U.S. $2,000,000 collected gross revenues. | |||||
| Charles River Laboratories, Inc. [Member] | ||||||
| Remaining commitment | $ 28,936 | |||||
| BICX Holding Company LLC [Member] | ||||||
| Common stock issued upon convertible debt | 2,227,575 | |||||
| Convertible Promissory Note | $ 4,160,000 | |||||
| Conversion agreement description | Pursuant to the Conversion Agreement, BICX has agreed that the Total Interest Payment (as defined in the Conversion Agreement) that would have been due under the Note, in the amount of $1,138,157, will be reflected on the Company’s financial statements as an amount due and owing to the Investor to be repaid within twelve (12) months of the closing of the Public Offering, or if the Public Offering is terminated or abandoned prior to closing, then on or before such date that is no later than twelve (12) months from the date of such termination or abandonment. | |||||
| Issuance price | $ 2.00 | |||||
| Amount due to investor | $ 1,138,157 | |||||
| Board Member [Member] | ||||||
| Stock options grant | 4,000 | |||||
| Term of options | 3 years | |||||
| Receive common stock equivalent | $ 5,000 | |||||
| Consulting services valued | 12,428 | |||||
| Alpine Creek [Member] | ||||||
| Royalty due | 91 | $ 91 | ||||
| Total consideration amount | 1,531,926 | |||||
| Payables to Alpine Creek | $ 1,215,000 | |||||
| Paid to Alpine Creek | $ 1,620,000 | |||||
| Payable commitment description | On any other proprietary implant distribution, that excludes the “treatment”, for alcohol and opioid addiction and for which no other payment is due, the Company shall pay 2.5% of the Company’s gross profit for implant distribution not to exceed $100 per sale. On or about January 1, 2021, Mr. Galligan acquired from Alpine Creek the rights to the royalty agreement by and between the Company and Alpine Creek. As of December 31, 2022 and 2021, there are no payments due | |||||
| Payable per treatment sold | $ 100 | |||||
| Profit holding percentage | 50.00% | |||||
| Lucido [Member] | ||||||
| Common stock, Shares issued | 200,000 | |||||
| common stock, par value | $ 0.001 |